SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (2003)1/6/2004 10:32:01 AM
From: Icebrg  Read Replies (3) of 3044
 
Ian

>> Since when were Ph IIs designed to evaluate efficacy?>>

That should be one of the prime objectives of a solid phase II design. Millennium has for about a year told us that they are looking for signals with regard to which (if any) additional cancers they should take into phase III. They cannot do so without having an idea about where there is efficacy to be found and where there is none. (It would be interesting to know whether this was a single-agent study or not).

These studies are however not powered to prove beyond any doubt that there is efficacy. Only that there might very well be some.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News